Manufacturing process optimization of ADMA Biologics' intravenous immunoglobulin products, BIVIGAM
Biological Products
/ isolation & purification
Chemical Fractionation
/ methods
Chromatography
/ methods
Humans
Immunity, Humoral
/ immunology
Immunoglobulins, Intravenous
/ isolation & purification
Immunologic Deficiency Syndromes
/ immunology
Immunotherapy
/ methods
Precision Medicine
/ methods
Treatment Outcome
ADMA
ASCENIV
BIVIGAM
IVIG
PIDD
RI-002
immunoglobulin
manufacture
optimization
primary immune deficiency disease
Journal
Immunotherapy
ISSN: 1750-7448
Titre abrégé: Immunotherapy
Pays: England
ID NLM: 101485158
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
pubmed:
10
10
2019
medline:
27
5
2020
entrez:
10
10
2019
Statut:
ppublish
Résumé
Humoral immunodeficiency patients require immunoglobulin replacement to prevent infection. Traditional intravenous immunoglobulin manufacturing methods have had the potential for containing impurities caused by physical, chemical and thermal stressors that alter proteins. Two intravenous immunoglobulin products, BIVIGAM
Identifiants
pubmed: 31596642
doi: 10.2217/imt-2019-0157
doi:
Substances chimiques
Biological Products
0
Immunoglobulins, Intravenous
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM